We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sanofi (SAN) Ordinary Euro 2

Sell:€90.65 Buy:€91.30 Change: €0.07 (0.08%)
Paris CAC 40:0.21%
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:€90.65
Buy:€91.30
Change: €0.07 (0.08%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:€90.65
Buy:€91.30
Change: €0.07 (0.08%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Contact details

Address:
46 Avenue de la Grande Armee
PARIS
75017
France
Telephone:
+33 (1) 53774000
Website:
https://www.sanofi.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SAN
ISIN:
FR0000120578
Market cap:
€115.22 billion
Shares in issue:
1.25 billion
Sector:
Pharmaceuticals
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
Paris CAC 40

Key personnel

  • Paul Hudson
    Chief Executive Officer, Executive Director, Member of the Executive Committee
  • Francois-Xavier Roger
    Chief Financial Officer, Member of the Executive Committee
  • Natalie Bickford
    Chief People Officer, Executive Vice President, Member of the Executive Committee
  • Roy Papatheodorou
    Executive Vice President, General Counsel, Member of the Executive Committee
  • Houman Ashrafian
    Executive Vice President, Head of Research and Development, Member of the Executive Committee
  • Olivier Charmeil
    Executive Vice President - General Medicines, Member of the Executive Committee
  • Audrey Derveloy
    Executive Vice President, Global Head of Corporate Affairs, Member of the Executive Committee
  • Emmanuel Frenehard
    Executive Vice President, Chief Digital Officer, Member of the Executive Committee
  • Brendan O'Callaghan
    Executive Vice President - Global Manufacturing and Supply, Member of the Executive Committee
  • Madeleine Roach
    Executive Vice President, Business Operations, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.